NCT05228314 - Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

September 23, 2022

Study Completion Date

April 23, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Candidate vaccine, SCB-2020S

a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19

BIOLOGICAL

Candidate vaccine, SCB-2019

a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

OTHER

Squalene based adjuvant

OTHER

CpG/alum adjuvant

Trial Locations (3)

Josha Research, Bloemfontein

Global Clinical Trials (Pty) Ltd, Pretoria

Wits Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, Soweto